Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study

Patients (n = 34) with previously untreated, slowly progressive asymptomatic stage I/II multiple myeloma or with stage II/III multiple myeloma in stable response/plateau phase following conventional anti-tumor therapy were immunized repeatedly with the antigen-specific cancer immunotherapeutic agent...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Hum Vaccin Immunother
Autori principali: Rossmann, Eva, Österborg, Anders, Löfvenberg, Eva, Choudhury, Aniruddha, Forssmann, Ulf, von Heydebreck, Anja, Schröder, Andreas, Mellstedt, Håkan
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2014
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4514088/
https://ncbi.nlm.nih.gov/pubmed/25483677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.29918
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi